The winning streak broke. Aurobindo Pharma shares slumped nearly 2% to ₹1,824 on Wednesday, halting an uninterrupted 12-day advance after the United States Food and Drug Administration wrapped up an audit of its active pharmaceutical ingredient manufacturing infrastructure in Telangana.
Profit-taking struck fast. Intraday trading saw the counter swing over 1.7% lower from a fresh 52-week high of ₹1,859.90, snapping one of the longest sustained rallies on the pharmaceutical index this quarter. Yet institutional conviction remains firm over the broader horizon. Aurobindo shares have gained 7% over the past month, soared more than 50% year-to-date, and now trade 65.16% above their 52-week floor of ₹1,106.00.
The immediate catalyst arrived through an exchange filing on Wednesday, November 11. The Hyderabad-based drugmaker confirmed that the USFDA concluded its inspection of Unit-II—an active pharmaceutical ingredient (API) facility operated by its wholly owned subsidiary, Apitoria Pharma Private Limited.
Federal inspectors audited the facility, situated at Gaddapotharam in Telangana's Sangareddy District, between September 7 and September 15, 2026. While the agency issued a Form 483, it subsequent formally classified the site as "Voluntary Action Indicated" (VAI) in its final Establishment Inspection Report. Crucially, the US regulator concluded and closed the inspection under Title 21 of the Code of Federal Regulations, Section 20.64.
Under federal regulatory guidelines, a VAI status indicates that USFDA inspectors detected objectionable conditions or manufacturing practices on-site, but determined that the infractions do not warrant administrative or enforcement action. Production and shipments face no immediate regulatory freeze.
Market Context: A Voluntary Action Indicated classification removes the threat of an Official Action Indicated (OAI) status or warning letter—the dual penalties that historically halt product approvals and disrupt export pipelines from Indian generic facilities to American hospitals and pharmacy chains.
Fundamentals continue to cushion the downside. The regulatory update follows a blowout second-quarter earnings release on November 4, where the pharmaceutical major delivered a 32.8% year-on-year surge in consolidated net profit to ₹1,126 crore for Q2FY27.
Top-line numbers reached an all-time peak. Revenue from operations leaped 23.9% to ₹10,263 crore—the highest quarterly figure in the company's operating history—surpassing the ₹8,286 crore clocked during the prior-year period. Operational efficiency expanded simultaneously. Earnings before interest, tax, depreciation, and amortisation (EBITDA) surged 28.4% year-on-year to ₹2,155 crore, up from ₹1,678 crore in Q2FY26.
| Financial Metric | Q2FY27 | Q2FY26 | YoY Growth (%) | Status / Level |
|---|---|---|---|---|
| Consolidated Net Profit | ₹1,126 Crore | ₹848 Crore | +32.8% | Expanded |
| Revenue from Operations | ₹10,263 Crore | ₹8,286 Crore | +23.9% | Record High |
| EBITDA | ₹2,155 Crore | ₹1,678 Crore |
Traders cashed out profits after twelve consecutive sessions in the green, using the Form 483 headlines to pare back elevated exposure. But with the USFDA officially closing the Apitoria docket without punitive sanctions, attention shifts back to commercial execution across the subsidiary's bulk drug portfolio and capacity ramp-ups heading into the second half of the fiscal year.
| +28.4% |
| Margin Growth |
| Intraday Low | ₹1,824.00 | — | -1.7% | 12-Day Run Snapped |
| 52-Week High | ₹1,859.90 | — | — | Hit Intraday |
| 52-Week Low | ₹1,106.00 | — | +65.16% | Trough Support |